- Home
- IPW vs SYBX Comparison
IPW vs SYBX Comparison
Compare IPW & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- SYBX
- Stock Information
- Founded
- IPW 2018
- SYBX N/A
- Country
- IPW United States
- SYBX United States
- Employees
- IPW N/A
- SYBX N/A
- Industry
- IPW Catalog/Specialty Distribution
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- IPW Consumer Discretionary
- SYBX Health Care
- Exchange
- IPW Nasdaq
- SYBX Nasdaq
- Market Cap
- IPW 19.8M
- SYBX 16.4M
- IPO Year
- IPW 2021
- SYBX N/A
- Fundamental
- Price
- IPW $0.53
- SYBX $1.45
- Analyst Decision
- IPW
- SYBX
- Analyst Count
- IPW 0
- SYBX 0
- Target Price
- IPW N/A
- SYBX N/A
- AVG Volume (30 Days)
- IPW 125.4K
- SYBX 41.1K
- Earning Date
- IPW 09-19-2025
- SYBX 08-07-2025
- Dividend Yield
- IPW N/A
- SYBX N/A
- EPS Growth
- IPW N/A
- SYBX N/A
- EPS
- IPW N/A
- SYBX N/A
- Revenue
- IPW $74,105,251.00
- SYBX N/A
- Revenue This Year
- IPW $8.31
- SYBX N/A
- Revenue Next Year
- IPW $77.15
- SYBX N/A
- P/E Ratio
- IPW N/A
- SYBX N/A
- Revenue Growth
- IPW N/A
- SYBX N/A
- 52 Week Low
- IPW $0.41
- SYBX $0.90
- 52 Week High
- IPW $2.36
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- IPW 44.04
- SYBX 50.39
- Support Level
- IPW $0.46
- SYBX $1.41
- Resistance Level
- IPW $0.54
- SYBX $1.58
- Average True Range (ATR)
- IPW 0.06
- SYBX 0.09
- MACD
- IPW 0.00
- SYBX -0.00
- Stochastic Oscillator
- IPW 47.11
- SYBX 24.14
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.